Early day motion tabled by primary sponsor Alan Meale (Labour), on Monday, 18 January 2010, in the House of Commons. It is signed by 43 members in total.
ALIMTA AND TREATMENT FOR MESOTHELIOMA SUFFERERS
That this House is aware that the anti-cancer drug Alimta is enormously beneficial in the treatment of mesothelioma tumours; recalls that sufferers in Scotland and parts of England and Wales have had access to the drug via cancer networks and primary care trusts; is therefore alarmed that the National Institute of Health and Clinical Excellence (NICE) has indicated that it is not minded to recommend Alimta for prescription to patients despite its known efficacy; and calls on the Government to ignore such advice, which deals mainly with NICE's narrow definition of cost effectiveness rather than the clinical needs of sufferers.
Secondary information
- Type
- Early day motion
- Reference
- 635
- Session
- 2009-10
- Other sponsors
- Jane Kennedy
- Gregory Campbell
- Andrew Dismore
- Graham Stringer
- Andrew Pelling
- Subjects
- Health services Diseases Medicine
- Link
- View this Early day motion on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-10-15 17:46:42 +0100
- URI
- http://data.parliament.uk/edms/40219
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/edms/40219
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/edms/40219